Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INCITE

Financiado

Cerrado

Immune Niches for Cancer ImmunoTherapy Enhancement

Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Without breakthroughs in treatment, cancer is likely to remain one of the biggest killers in th... ver más

30/04/2025

SINTEF

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

SINTEF AS No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-21

FETOPEN-01-2018-2019-2020: FET-Open Challenging Current Thinki...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

SINTEF

710.00K€ | Lider

BCC

338.88K€ | Participante

STIFTUNG LEIBNIZINSTITUT FUR...

389.14K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

T-OP Training Network for Optimizing Adoptive T cell Therapy of C... 4M€ Cerrado

T-RAFIC Training network for tracking and controlling therapeutic im... Cerrado

Exh-Res-CART Exhaustion resistant CAR T cells for the treatment of solid... 161K€ Cerrado

ARMOR-T Armoring multifunctional T cells for cancer therapy 2M€ Cerrado

ROLE OF TCR AFFINITY Study and modification of T cell receptor structure to enhan... 100K€ Cerrado

STEMIMMUNE Improving adoptive T cell transfer immunotherapy for cancer... 100K€ Cerrado

Duración del proyecto: 52 meses Fecha Inicio: 2020-12-21
Fecha Fin: 2025-04-30

Líder del proyecto

SINTEF AS No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Without breakthroughs in treatment, cancer is likely to remain one of the biggest killers in the 21st century. Immunotherapy of cancer by checkpoint inhibitors, vaccines or adoptive T cell therapy is coming of age and has the potential to cure cancer, but is still hampered by some major limitations. For instance, Adoptive Cell Therapy (ACT) with unmanipulated or engineered T cells (TCR-transgenic and CAR-T cells) has indeed demonstrated success in the treatment of patients affected by leukemias, but is much less effective against lymphomas and solid tumors. One likely explanation is that we do not educate the right type of anti-tumor T cells. The T cells considered to be the gold standard for tumor therapy have stem cell memory features, but the proper and safe way to generate these fit T cells for clinical purposes is still an unresolved matter. Here we propose an advanced transformative technology termed INCITE, utilizing a novel high-resolution 3D microfabrication technology to engineer a specially tailored microenvironment that will be inhabited by cells central for T cells education in order to generate the fittest anti-tumor T cells for advanced adoptive T cell therapy. INCITE will bring together a transdisciplinary consortium capable of developing this innovative platform by combining state-of-the-art 3D printing, computer modeling, bioengineering, bioinformatics, immunology, developmental and cancer biology approaches, toward the development of a functional immune niche for selection and expansion of tumor-rejecting T cells. The INCITE platform will revolutionize the treatment of cancer patients with ACT, with a profound impact on the quality of life and well-being of millions of people.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores